Hepatocellular carcinoma: Systemic therapies and future perspectives

Sameh Mikhail, David Cosgrove, Amer Zeidan

Research output: Contribution to journalReview articlepeer-review

Abstract

Hepatocellular carcinoma is (HCC) the most common primary malignancy of the liver in adults. It is also the fifth most common solid cancer worldwide and the third leading cause of cancer-related deaths. Treatment options for HCC include liver transplantation, surgical resection, locoregional therapies and chemotherapy. The median survival time of patients following the diagnosis of unresectable disease is approximately 6-20 months, whereas the 5-year survival is less than 5%. Given the projected increase in incidence of HCC due to hepatitis C virus infection and obesity related cirrhosis, there is an urgent need for more intensive research in this cancer. In this article, we review the systemic options available for patients with HCC, its molecular pathogenesis and future therapeutic directions with special emphasis on immune-based and molecularly-targeted therapy.

Original languageEnglish (US)
Pages (from-to)1205-1218
Number of pages14
JournalExpert Review of Anticancer Therapy
Volume14
Issue number10
DOIs
StatePublished - Oct 1 2014

Keywords

  • biomarkers
  • hepatocellular carcinoma
  • immune therapy
  • liver transplantation
  • locoregional therapy
  • partial hepatectomy
  • sorafenib

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Hepatocellular carcinoma: Systemic therapies and future perspectives'. Together they form a unique fingerprint.

Cite this